Welcure Drugs & Pharmaceuticals Share Price Appears Down 91% at ₹0.74 as Stock Trades Ex-Bonus and Ex-Split Today

New Delhi, October 16: Welcure Drugs & Pharmaceuticals Limited share price started the trading session by falling 91% today, on October 16. However, the significant decline in the share price is not real monetary loss, but just an adjustment to the ₹10 to ₹1 stock split and 1:10 bonus issue. In reality, the stock is up by 4.05%, or 0.03 points, and is currently trading at ₹0.77. The current traded volume stands at 1.42 crore shares, with the company’s market cap at ₹91 crore. The stock has surged nearly 4,000% over the past decade, driven by sustained investor interest and rising optimism in India’s low-cap pharmaceutical segment.

Welcure Drugs & Pharmaceuticals Limited is an Indian company that is engaged in the manufacturing and trading of pharmaceutical products. The company was established in 1996, and is headquartered in New Delhi. The shares of the company are listed on BSE with the ticker symbol 524661.

Dual Corporate Action of Stock Split and Bonus Issue

The company executed dual corporate actions including a stock split of ₹10 to ₹1 per share and a bonus issue of 1:10. For both the corporate actions, the share price adjusted today proportionately. Hence, the share price appeared down by 91%. However, this will not affect the investment value of shareholders as the share price has fallen in regards to eligible shareholders holding 110 more shares now after the dual corporate actions.

The dual corporate actions will help the company attract more investors by reducing the share price and making it more affordable to the investors. Furthermore, it will also help increase the overall liquidity.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations